The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ekusheva E.V.

Federal Research and Clinical Centre for Specialized Medical Care and Medical Technologies;
Belgorod State National Research University

Voitenkov V.B.

Pediatric Research and Clinical Center for Infectious Diseases

Rizakhanova O.A.

North-Western State Medical University named after I.I. Mechnikov

The effectiveness of cytoflavin in complex therapy of patients with the coronavirus infection COVID-19

Authors:

Ekusheva E.V., Voitenkov V.B., Rizakhanova O.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(12): 33‑39

DOI: 10.17116/jnevro202112112133

Read: 9849 times

Download PDF (RU)
Contact the author
Table of contents

THE EFFECTIVENESS OF CYTOFLAVIN IN COMPLEX THERAPY OF PATIENTS WITH THE CORONAVIRUS INFECTION COVID-19
THE EFFECTIVENESS OF CYTOFLAVIN IN COMPLEX THERAPY OF PATIENTS WITH THE CORONAVIRUS INFECTION COVID-19

To cite this article:

Ekusheva EV, Voitenkov VB, Rizakhanova OA. The effectiveness of cytoflavin in complex therapy of patients with the coronavirus infection COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(12):33‑39. (In Russ.)
https://doi.org/10.17116/jnevro202112112133

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The role of drug Cyto­flavin in the correction of dysautonomia in patients with post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):140-146
Effi­ciency of complex medi­cal reha­bilitation after pulmonary enda­rterectomy. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):629-636
Loca­lization features of FAP-positive acti­vated stro­mal cells in fibrosis in patients with new coro­navirus infe­ction COVID-19. Russian Journal of Archive of Pathology. 2024;(6):5-14
Lapa­roscopic appe­ndectomy for appe­ndiceal muco­cele in a patient with COVID-19. Endo­scopic Surgery. 2024;(6):41-45
Sano­genetic commonality of ultraviolet irra­diation of blood and intravenous ozone therapy. Choice of the opti­mal method of this impact for reha­bilitation of patients after nephrolitholapaxy. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(4):95-99
Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data). Russian Journal of Preventive Medi­cine. 2024;(12):114-121
Orga­nizational issues of reproductive health protection of adolescent girls in the system of the Fede­ral Medi­cal and Biological Agency of Russia. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):7-13
Physical medi­cal reha­bilitation of patients with dystrophinopathies: dyna­mics of the disease’s course considering clinical anthropometric indi­cators. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):31-39
Influence of inte­rmittent pneumatic compression on microvasculature condition in lymphedema. Prospective randomized clinical trial. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):48-53
Sele­ctive anosmia for mono­molecular odorants in a cohort of young indi­viduals. Russian Rhinology. 2024;(4):262-268
Abstract:

OBJECTIVE

To study therapy, including a sequential course of the drug Cytoflavin, on the dynamics of neurological and general status in patients with new coronavirus infection COVID-19.

MATERIAL AND METHODS

47 patients with a new coronavirus infection COVID-19, admitted to the hospital and having a state of moderate severity, according to the criteria of the Interim Guidelines of the Ministry of Health of the Russia for the prevention, diagnosis and treatment of a new coronavirus infection (COVID-19, version 9 of 10.26.2020). Clinical and neurological research, laboratory and instrumental examination methods were used before and after the course of therapy.

RESULTS

When a sequential Cytoflavin regimen is used in patients with COVID-19 infection, along with standard therapy, a significant improvement in neurological and general status is observed, as well as a significant positive dynamics in the results of laboratory and instrumental research methods (markers of a systemic inflammatory response, hemostasis and oxygenation disorders), which indicates on the influence of the significant effect of Cytoflavin on the processes of inflammation and hypercoagulability in COVID-19 infection.

CONCLUSION

The use of the drug Cytoflavin in the complex therapy of patients with COVID-19 infection is pathogenetically justified and expedient. The data obtained make it possible to recommend the inclusion of Cytoflavin in the treatment protocols for patients with COVID-19 coronavirus infection to optimize therapy and improve the course and outcome of the disease, as well as a longer use of Cytoflavin and repeated courses of its use in patients with COVID-19 infection.

Keywords:

coronavirus infection
COVID-19
rehabilitation
Cytoflavin
recovery from COVID-19

Authors:

Ekusheva E.V.

Federal Research and Clinical Centre for Specialized Medical Care and Medical Technologies;
Belgorod State National Research University

Voitenkov V.B.

Pediatric Research and Clinical Center for Infectious Diseases

Rizakhanova O.A.

North-Western State Medical University named after I.I. Mechnikov

Received:

08.11.2021

Accepted:

09.11.2021

Close metadata

References:

  1. Desforges M, Coupanec AL, Dubeau P, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12(1):14-20.  https://doi.org/10.3390/v12010014
  2. Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood — brain barrier. Neurobiology of Diseases. 2020;146:105131. https://doi.org/10.1016/j.nbd.2020.105131
  3. Mori I. Transolfactory neuroinvasion by viruses threatens the human brain. Acta Virologica. 2015;59:338-349.  https://doi.org/10.4149/av_2015_04_338
  4. Singh AK, Bhushan B, Maurya A, et al. Novel coronavirus disease 2019 (COVID-19) and neurodegenerative disorders. Dermatologic Therapy. 2020;33(4):13591. https://doi.org/10.1111/dth.13591
  5. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clinical Immunology. 2020;215:108427. https://doi.org/10.1016/j.clim.2020.108427
  6. Belopasov VV, Yachou Y, Samoilova EM, Baklaushev VP. The nervous system damage in COVID-19. Klinicheskaya Praktika. 2020;11(2):60-80. (In Russ.). https://doi.org/10.17816/clinpract34851
  7. Iqbal FM, Lam K, Sounderajah V, Clarke JM, et al. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinical Medicine. 2021;36:100899. https://doi.org/10.1016/j.eclinm.2021.100899
  8. Jacobson KB, Rao M, Bonilla H, et al. Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clinical Infectious Diseases. 2021;73(3):826-829.  https://doi.org/10.1093/cid/ciab103
  9. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nature Medicine. 2021;27(4):626-631.  https://doi.org/10.1038/s41591-021-01292-y
  10. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. MedRxiv. 2021: 2021.01.27.21250617. https://doi.org/10.1101/2021.01.27.21250617
  11. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. https://doi.org/10.1371/journal.pone.0240784
  12. Desai AD, Boursiquot BC, Melki L, Wan EY. Management of arrhythmias associated with COVID-19. Current Cardiology Reports. 2020;23(1):2.  https://doi.org/10.1007/s11886-020-01434-7
  13. Kanjwal K, Jamal S, Kichloo A, Grubb BP. New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection. The Journal of Innovation in Cardiac Rhythm Management. 2020;11(11):4302-4304. https://doi.org/10.19102/icrm.2020.111102
  14. Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with non-critical COVID-19 two months after symptoms’ onset. Clinical Microbiol and Infection. 2021;27(2):258-263.  https://doi.org/10.1016/j.cmi.2020.09.052
  15. Annweiler C, Sacco G, Salles N, et al. National French survey of Coronavirus disease (COVID-19) symptoms in people aged 70 and over. Clinical Infectious Diseases. 2021;72(3):490-494.  https://doi.org/10.1093/cid/ciaa792
  16. Hellmuth J, Barnett TA, Asken BM, et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. The Journal of Neurovirology. 2021;27(1):191-195.  https://doi.org/10.1007/s13365-021-00954-4
  17. Batty GD, Deary IJ, Luciano M, et al. Psychosocial factors and hospitalisations for COVID-19: Prospective cohort study based on a community sample. Brain, Behavior, and Immunity. 2020;89:569-578.  https://doi.org/10.1016/j.bbi.2020.06.021
  18. Almeria M, Cejudo JC, Sotoca J, et al. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain, Behavior, & Immunity — Health. 2020;9:100163. https://doi.org/10.1016/j.bbih.2020.100163
  19. Gu Y, Zhu Y, Xu F, et al. Factors associated with mental health outcomes among patients with COVID-19 treated in the Fangcang shelter hospital in China. Asia-Pacific Psychiatry. 2021;13:e12443. https://doi.org/10.1111/appy.12443
  20. Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. The Clinical Medicine (Lond). 2021;21(1):63-67.  https://doi.org/10.7861/clinmed.2020-0896
  21. Davido B, Seang S, Tubiana R, de Truchis P. Post-COVID-19 chronic symptoms: a postinfectious entity? Clinical Microbiology and Infection. 2020;26(11):1448-1449. https://doi.org/10.1016/j.cmi.2020.07.028
  22. Goldstein DS. The extended autonomic system, dyshomeostasis and COVID-19. Clinical Autonomic Research. 2020;30(4):299-315.  https://doi.org/10.1007/s10286-020-00714-0
  23. Umapathi T, Poh MQW, Fan BE, et al. Acute hyperhidrosis and postural tachycardia in a COVID-19 patient. Clinical Autonomic Research. 2020;30(6):571-573.  https://doi.org/10.1007/s10286-020-00733-x
  24. Miglis MG, Prieto T, Shaik R, et al. A case report of postural tachycardia syndrome after COVID-19. Clinical Autonomic Research. 2020;30(5):449-451.  https://doi.org/10.1007/s10286-020-00727-9
  25. Saeed S, Tadic M, Larsen TH, et al. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. Journal of Hypertension. 2021;39(7):1282-1292. https://doi.org/10.1097/HJH.0000000000002819
  26. Summary of ICD coding for COVID-19.  https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-for-COVID-19-disease-outbreak
  27. Temporary guidelines. Prevention, diagnosis and treatment of coronavirus infection (COVID-19). Version 12. (21.09.21). 2021;232. (In Russ.). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/%D0%92%D0%9C%D0%A0_COVID-19_V12.pdf
  28. Fedin AI, Rumyantseva SA, Piradov MA, et al. Clinical efficacy of Cytoflavin in patients with chronic cerebral ischemia (multicenter, placebo-controlled, randomized trial. Vrach. 2007;4(12):29-34. (In Russ.).
  29. Polunina AG, Osinovskaya NA, Gudkova AN, Guekht AB. Influence of cytoflavin on symptoms of asthenia, emotional disorders and autonomic regulation in patients with organic asthenic disorder. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;2:28-33 (In Russ.).
  30. Shabanov PD, Mokrenko EV. Synthetic inducers of interferon in the treatment and prevention of acute inflammatory diseases of the upper respiratory tract. Poliklinika. 2015;3:117-120. (In Russ.).
  31. Parfenov SA, Belov VG, Parfenov JuA. Dynamics of indicators of the functional state of the central nervous system in the operators of the Navy after a long working cycle while taking Cytoflavin. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(8):55-58. (In Russ.). https://doi.org/10.17116/jnevro20171178155-58
  32. Parfenov YuA, Vasilevskaya MA, Parfenov SA, et al. Justification of indications for the use of biofeedback therapy and cytoflavin in the treatment of neurological complications of osteochondrosis among elderly patients. Georgian Medical News. 2018;283:89-96. (In Russ.).
  33. Temporary guidelines. Prevention, diagnosis and treatment of coronavirus infection (COVID-19). Version 9. (26.10.20). 2020;236. (In Russ.). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf
  34. Ekusheva EV. The role of succinate-containing drugs in the processes of neuroplasticity after ischemic stroke. Eksperimental’naya i Klinicheskaya Farmakologiya. 2018;8(81):37-44. (In Russ.). https://doi.org/10.30906/0869-2092-2018-81-8-37-44
  35. Xie N, Zhang L, Gao W, et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduction and Targeted Therapy. 2020;5:227.  https://doi.org/10.1038/s41392-020-00311-7
  36. Heer CD, Sanderson DJ, Voth LS, et al. Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable of innate immunity. Metabolism. 2020;295(52):17986-17996. https://doi.org/10.1074/jbc.RA120.015138
  37. Mehmel M, Jovanović N, Spitz U. Nicotinamide riboside-the current state of research and therapeutic uses. Nutrients. 2020;12(6):1616. https://doi.org/10.3390/nu12061616
  38. Omran HM, Almaliki MS. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis. Journal of Infection and Public Health. 2020;13(9):1196-1201. https://doi.org/10.1016/j.jiph.2020.06.004
  39. Badawy AA. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. Bioscience Reports. 2020;40(10):BSR20202856. https://doi.org/10.1042/BSR20202856
  40. Haskó G, Kuhel DG, Németh ZH, et al. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. The Journal Immunology. 2000;164(2):1013-1019. https://doi.org/10.4049/jimmunol.164.2.1013
  41. Welihinda AA, Kaur M, Raveendran KS, Amento EP. Enhancement of inosine-mediated A2AR signaling through positive allosteric modulation. Cell Signaling Technology. 2018;42:227-235.  https://doi.org/10.1016/j.cellsig.2017.11.002
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.